The PISCES study was a randomized, double-blind trial involving 1,228 maintenance hemodialysis patients in Canada and Australia[1]. Patients received either daily fish oil (4 g omega-3 polyunsaturated fatty acids including 1.6 g EPA and 0.8 g DHA) or a corn oil placebo[1]. During 3.5 years of follow-up, the rate of major cardiovascular events was significantly lower in the fish oil group (0.31 vs. 0.61 per 1,000 patient-days; hazard ratio 0.57; p<0.001)[1]. Fish oil reduced the risk of cardiac death by 45%, myocardial infarction by 44% and stroke by 63%[5]. Side effects were minimal – major bleeding occurred in 4.8% of patients in the fish oil group and 7.6% in the placebo group[2]. A study has shown that daily omega-3 fatty acid supplementation is a safe and effective intervention to reduce cardiovascular events in hemodialysis patients[1].